MX2007007586A - Composiciones de proteinas de virus de gripe y metodos de uso de las mismas. - Google Patents

Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.

Info

Publication number
MX2007007586A
MX2007007586A MX2007007586A MX2007007586A MX2007007586A MX 2007007586 A MX2007007586 A MX 2007007586A MX 2007007586 A MX2007007586 A MX 2007007586A MX 2007007586 A MX2007007586 A MX 2007007586A MX 2007007586 A MX2007007586 A MX 2007007586A
Authority
MX
Mexico
Prior art keywords
compositions
influenza viral
methods
viral proteins
fusion proteins
Prior art date
Application number
MX2007007586A
Other languages
English (en)
Spanish (es)
Inventor
Thomas J Powell
Valerian Nakaar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of MX2007007586A publication Critical patent/MX2007007586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007007586A 2004-12-21 2005-12-21 Composiciones de proteinas de virus de gripe y metodos de uso de las mismas. MX2007007586A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30
PCT/US2005/046662 WO2006069262A2 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2007007586A true MX2007007586A (es) 2007-12-10

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007586A MX2007007586A (es) 2004-12-21 2005-12-21 Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.

Country Status (9)

Country Link
EP (1) EP1831259A2 (enExample)
JP (1) JP2008524261A (enExample)
AU (2) AU2005319141B8 (enExample)
BR (1) BRPI0519705A2 (enExample)
CA (1) CA2593746A1 (enExample)
MX (1) MX2007007586A (enExample)
NZ (1) NZ556004A (enExample)
SG (1) SG160424A1 (enExample)
WO (1) WO2006069262A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
EP2012829A4 (en) * 2006-04-24 2010-04-21 Protelix Inc PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS
EP2517723B1 (en) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
WO2008157419A2 (en) * 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
US20130095130A1 (en) * 2010-01-06 2013-04-18 Vaxinnate Corporation Methods and Compositions for Providing Protective Immunity in the Elderly
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014070848A1 (en) * 2012-11-05 2014-05-08 Georgia State University Research Foundation Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569225B2 (en) * 2002-08-12 2009-08-04 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and B-cell epitopes
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE

Also Published As

Publication number Publication date
CA2593746A1 (en) 2006-06-29
BRPI0519705A2 (pt) 2009-03-10
WO2006069262A2 (en) 2006-06-29
JP2008524261A (ja) 2008-07-10
EP1831259A2 (en) 2007-09-12
AU2005319141B8 (en) 2010-03-18
SG160424A1 (en) 2010-04-29
WO2006069262A3 (en) 2007-02-01
AU2010200048A1 (en) 2010-01-28
AU2005319141B2 (en) 2010-02-18
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
FR20C1016I1 (enExample)
EP1490094A4 (en) ANTIBODY FUSION PROTEINS: EFFECTIVE ADJUVANTIES IN PROTEIN VACCINATION
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
DK1699822T3 (da) IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
PL1615945T3 (pl) Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
SG165353A1 (en) Improved human interferon molecules and their uses
DE602004029015D1 (de) Hochkonzentrierter antikörper und proteinformulierungen
DK1939281T3 (da) Immortaliserede andecellelinjer til virusproduktion
EP2089053A4 (en) HPV ANTIGEN FUSION PROTEIN VACCINE COMPOUNDS AND ITS USES
MXPA05009580A (es) Vacuna contra el virus de la influenza.
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
WO2007053188A3 (en) Production of multivalent virus like particles
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use
ATE389397T1 (de) Adjuvante zusammensetzungen
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
EP1578772A4 (en) CYTOKINS AND CYTOKIN RECEPTORS WITH REDUCED IMMUNOGENICITY
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods

Legal Events

Date Code Title Description
FA Abandonment or withdrawal